- Accelerating Brazilian 바카라 베팅 launch this year… Expanding exports with GMP certification
- Enhancing medical staff training and KOL 바카라 베팅ing efforts in Thailand

Source: 바카라 베팅
Source: 바카라 베팅

[by Sung, Jae Jun] Inibio announced on July 22 that it has received product approval for its botulinum toxin product, ‘Inibo,’ from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID). This marks the company’s second overseas approval in the Latin American market, following Thailand, as it accelerates efforts to expand its global market presence.

Peru represents a rapidly growing market for aesthetic medicine, and this product approval is anticipated to serve as an opportunity to strengthen the brand positioning of ‘Inibo’ in the Latin American market. Inibio previously signed an exclusive distribution agreement in 2022 with a local partner specializing in medical aesthetics.

Leveraging its entry into the Peruvian market as a springboard, 바카라 베팅 plans to accelerate sales expansion in Brazil within the year. Following its official launch in Thailand, the company is actively enhancing local marketing efforts, including regular training programs for medical professionals, webinars, and the operation of a brand ambassador, while also strengthening collaborations with key opinion leaders (KOLs). On July 14, 바카라 베팅 hosted a factory tour and hands-on training session for about 20 participants, including Thai medical personnel and clinic representatives.

“Following the submission of the New Drug Application (NDA) in China and the acquisition of GMP (Good Manufacturing Practices) certification from the Brazilian Health Regulatory Agency (ANVISA), we are laying the groundwork for global expansion by securing our first product approval in Latin America, namely Peru,” an Inibio official said. “We will raise Inibio’s presence in the global market through tailored strategies for each country.”

바카라 베팅, founded in 2017, is a biopharmaceutical company that operates the largest single GMP-certified production facility in Korea, located in Bucheon, Gyeonggi Province. Since its merger with GC Wellbeing in April, the company has been actively strengthening its global expansion efforts and pursuing pipeline co-development strategies utilizing its global network.

저작권자 © 더바이오 무단전재 및 재배포 금지